Chronic pain affects 50% of adults with sickle cell disease (SCD). Although inflammation is thought to contribute to the pathogenesis of chronic pain, no studies have examined the differences in circulating cytokines between patients with SCD with and without chronic pain. We performed an observational cohort study using blood and urine samples from adults with SCD with and without chronic pain at their usual state of health. We tested the hypothesis that, compared to those without chronic pain, those with chronic pain would have significantly higher baseline circulating proinflammatory cytokines. A total of 61 adults with SCD, 40 with chronic pain and 21 without chronic pain were tested. When SCD patients with chronic pain were compared to those without chronic pain, no significant differences in cytokine levels were noted. The variables most associated with the diagnosis of chronic pain in this population were opioid dose and subject age.

1.
Ballas
SK
.
Pathophysiology and principles of management of the many faces of the acute vaso-occlusive crisis in patients with sickle cell disease
.
Eur J Haematol
.
2015
Aug
;
95
(
2
):
113
23
.
[PubMed]
0902-4441
2.
Zhang
D
,
Xu
C
,
Manwani
D
,
Frenette
PS
.
Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology
.
Blood
.
2016
Feb
;
127
(
7
):
801
9
.
[PubMed]
0006-4971
3.
Dampier
C
,
Palermo
TM
,
Darbari
DS
,
Hassell
K
,
Smith
W
,
Zempsky
W
.
AAPT Diagnostic Criteria for Chronic Sickle Cell Disease Pain
.
J Pain
.
2017
May
;
18
(
5
):
490
8
.
[PubMed]
1526-5900
4.
Smith
WR
,
Penberthy
LT
,
Bovbjerg
VE
,
McClish
DK
,
Roberts
JD
,
Dahman
B
, et al
Daily assessment of pain in adults with sickle cell disease
.
Ann Intern Med
.
2008
Jan
;
148
(
2
):
94
101
.
[PubMed]
0003-4819
5.
Brandow
AM
,
Stucky
CL
,
Hillery
CA
,
Hoffmann
RG
,
Panepinto
JA
.
Patients with sickle cell disease have increased sensitivity to cold and heat
.
Am J Hematol
.
2013
Jan
;
88
(
1
):
37
43
.
[PubMed]
0361-8609
6.
Brandow
AM
,
Hansen
K
,
Nugent
M
,
Pan
A
,
Panepinto
JA
,
Stucky
CL
.
Children and adolescents with sickle cell disease have worse cold and mechanical hypersensitivity during acute painful events
.
Pain
.
2019
Feb
;
160
(
2
):
407
16
.
[PubMed]
0304-3959
7.
Field
JJ
,
Ballas
SK
,
Campbell
CM
,
Crosby
LE
, et al
Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks-American Pain Society-American Academy of Pain Medicine Pain Taxonomy Diagnostic Criteria for Acute Sickle Cell Disease Pain
.
J Pain
.
2018
Jul
;
20
(
7
):
746
59
.
[PubMed]
1526-5900
8.
Rezaei
E
,
Hogan
D
,
Trost
B
,
Kusalik
AJ
,
Boire
G
,
Cabral
DA
, et al
Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis
.
Rheumatology (Oxford)
.
2020
Jan
;
•••
:
kez615
. ;
Epub ahead of print
.
[PubMed]
1462-0324
9.
Pardeo
M
,
Bracaglia
C
,
De Benedetti
F
.
Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies
.
Best Pract Res Clin Rheumatol
.
2017
Aug
;
31
(
4
):
505
16
.
[PubMed]
1521-6942
10.
Rodriguez-Pintó
I
,
Agmon-Levin
N
,
Howard
A
,
Shoenfeld
Y
.
Fibromyalgia and cytokines
.
Immunol Lett
.
2014
Oct
;
161
(
2
):
200
3
.
[PubMed]
0165-2478
11.
Kutu
FC
,
Özdolap
Ş
,
Sarikaya
S
.
Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia
.
Arch Rheumatol
.
2018
Aug
;
34
(
2
):
123
9
.
[PubMed]
2618-6500
12.
Perini
F
,
D’Andrea
G
,
Galloni
E
,
Pignatelli
F
,
Billo
G
,
Alba
S
, et al
Plasma cytokine levels in migraineurs and controls
.
Headache
.
2005
Jul-Aug
;
45
(
7
):
926
31
.
[PubMed]
0017-8748
13.
Uzar
E
,
Evliyaoglu
O
,
Yucel
Y
,
Ugur Cevik
M
,
Acar
A
,
Guzel
I
, et al
Serum cytokine and pro-brain natriuretic peptide (BNP) levels in patients with migraine
.
Eur Rev Med Pharmacol Sci
.
2011
Oct
;
15
(
10
):
1111
6
.
[PubMed]
1128-3602
14.
Sarray
S
,
Saleh
LR
,
Lisa Saldanha
F
,
Al-Habboubi
HH
,
Mahdi
N
,
Almawi
WY
.
Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition
.
Cytokine
.
2015
Mar
;
72
(
1
):
43
7
.
[PubMed]
1043-4666
15.
Brandow
AM
,
Wandersee
NJ
,
Dasgupta
M
,
Hoffmann
RG
,
Hillery
CA
,
Stucky
CL
, et al
Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use
.
Br J Haematol
.
2016
Oct
;
175
(
2
):
237
45
.
[PubMed]
0007-1048
16.
Qari
MH
,
Dier
U
,
Mousa
SA
.
Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease
.
Clin Appl Thromb Hemost
.
2012
Mar-Apr
;
18
(
2
):
195
200
.
[PubMed]
1076-0296
17.
Cook
EF
,
Goldman
L
.
Empiric comparison of multivariate analytic techniques: advantages and disadvantages of recursive partitioning analysis
.
J Chronic Dis
.
1984
;
37
(
9-10
):
721
31
.
[PubMed]
0021-9681
18.
Ji
RR
,
Nackley
A
,
Huh
Y
,
Terrando
N
,
Maixner
W
.
Neuroinflammation and Central Sensitization in Chronic and Widespread Pain
.
Anesthesiology
.
2018
Aug
;
129
(
2
):
343
66
.
[PubMed]
0003-3022
19.
Baral
P
,
Udit
S
,
Chiu
IM
.
Pain and immunity: implications for host defence
.
Nat Rev Immunol
.
2019
Jul
;
19
(
7
):
433
47
.
[PubMed]
1474-1733
20.
Koch
A
,
Zacharowski
K
,
Boehm
O
,
Stevens
M
,
Lipfert
P
,
von Giesen
HJ
, et al
Nitric oxide and pro-inflammatory cytokines correlate with pain intensity in chronic pain patients
.
Inflamm Res
.
2007
Jan
;
56
(
1
):
32
7
.
[PubMed]
1023-3830
21.
Iwakura
Y
,
Nakae
S
,
Saijo
S
,
Ishigame
H
.
The roles of IL-17A in inflammatory immune responses and host defense against pathogens
.
Immunol Rev
.
2008
Dec
;
226
(
1
):
57
79
.
[PubMed]
0105-2896
22.
Duits
AJ
,
Pieters
RC
,
Saleh
AW
,
van Rosmalen
E
,
Katerberg
H
,
Berend
K
, et al
Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis
.
Clin Immunol Immunopathol
.
1996
Oct
;
81
(
1
):
96
8
.
[PubMed]
0090-1229
23.
Kato
GJ
,
Martyr
S
,
Blackwelder
WC
,
Nichols
JS
,
Coles
WA
,
Hunter
LA
, et al
Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality
.
Br J Haematol
.
2005
Sep
;
130
(
6
):
943
53
.
[PubMed]
0007-1048
24.
Vilas-Boas
W
,
Veloso Cerqueira
BA
,
Figueiredo
CV
,
Santiago
RP
,
da Guarda
CC
,
Pitanga
TN
, et al
Association of homocysteine and inflammatory-related molecules in sickle cell anemia
.
Hematology
.
2016
Mar
;
21
(
2
):
126
31
.
[PubMed]
1607-8454
25.
Karafin
MS
,
Singavi
A
,
Hussain
J
,
Wandersee
N
,
Heinrich
T
,
Hurley
RW
, et al
Predictive factors of daily opioid use and quality of life in adults with sickle cell disease
.
Hematology
.
2018
Dec
;
23
(
10
):
856
63
.
[PubMed]
1607-8454
26.
Carroll
CP
,
Lanzkron
S
,
Haywood
C
 Jr
,
Kiley
K
,
Pejsa
M
,
Moscou-Jackson
G
, et al
Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease
.
Am J Prev Med
.
2016
Jul
;
51
(
1
Suppl 1
):
S69
77
.
[PubMed]
0749-3797
27.
Li
X
,
Angst
MS
,
Clark
JD
.
Opioid-induced hyperalgesia and incisional pain
.
Anesth Analg
.
2001
Jul
;
93
(
1
):
204
9
.
[PubMed]
0003-2999
28.
Yi
P
,
Pryzbylkowski
P
.
Opioid Induced Hyperalgesia
.
Pain Med
.
2015
Oct
;
16
Suppl 1
:
S32
6
.
[PubMed]
1526-2375
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.